Development of pre-clinical patient-derived xenograft models of myelodysplastic syndromes (WP3)
Rationale and objectives
One major drawback of myelodysplastic syndromes (MDS) modeling is the ineffectiveness of the MDS cells engraftment in the mouse. We will overcome this problem by developing new humanized mouse patient-derived xenograft (PDX) models.
Our specific objectives are:
• To develop and optimize new humanized mouse strains and microenvironments mimicking the human bone marrow.
• To evaluate the engraftment potential of MDS patient cells using the new tools in PDX mouse models.
• To study the maintenance of cell disease heterogeneity during engraftment using single cell RNA-seq.
Klinikum rechts der Isar der TU München (Germany, 4 months), GenomeScan B.V. (The Netherlands, 1 month).
PhD in Clinical Science, University of Bergen (UiB), Norway.